26 May 2026
AGC Biologics Starts NN4101 Bispecific Antibody Development and GMP Production
With Novelty Nobility, moves Copenhagen cell‑line/MCB work to GMP manufacturing in Chiba from May 2026. Targets retinal neovascular disease; global cGMP network enables tech transfer.